Diagnostics specialists in charge.

Acquired RDI in 2017 and has led the company since — building the team, the systems, and the physician network that let customers of every size benefit from RDI's specialist focus. Holds degrees in pre-med and economics from Columbia. Before RDI, invested in and operated businesses across software startups and public companies up to $2.5B in revenue.

Leads all operations at RDI — sample collection teams and the CLIA lab. Most recently ran Global Lab Operations at NeoGenomics. Before that, business services and clinical operations at Beaufort, an IVD CRO. B.S. in biochemistry from UCLA. Developed and validated 80+ assays across a career at LabCorp, Genzyme, One Lambda (Thermo Fisher), Pathway Diagnostics (Quest), and Amgen.

Licensed physician and board-certified pathologist. Previously CMO at Roche Diagnostics, Ortho-Clinical Diagnostics, and Beckman Coulter. Before industry, directed the Hematology/Oncology Center for Quest Diagnostics and served as associate professor of pathology at UC-Irvine. Harvard Medical School graduate. 70+ peer-reviewed publications.

Principal investigator for RDI's prospective collections. Formally trained scientist with a career developing, validating, and launching new diagnostic products — critical in obtaining 510(k), EUA, and CE approval for immunological assays, cancer biomarkers, and genetic molecular assays. Ph.D. in human physiology and biochemistry from the University of Zurich. M.S. in biology from University of Insubria.

20+ years in IVD R&D and regulatory. Chemical engineer by training. Senior roles at Abbott and SQI Diagnostics. Specializes in FDA and global regulatory strategy, Q-submissions, and pathway design for diagnostics companies building toward clearance.

25+ years across IVD quality, compliance, and operations. Most recently directed quality strategy for Abbott's global toxicology business, scaling a compliant QMS across 17+ global sites. Deep expertise in ISO/IEC 17025 and FDA inspection readiness.